110 related articles for article (PubMed ID: 26631611)
1. Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells.
Nielsen JS; Sedgwick CG; Shahid A; Zong Z; Brumme ZL; Yu S; Liu L; Kroeger DR; Treon SP; Connors JM; Gascoyne RD; Berry BR; Marra MA; Morin RD; Macpherson N; Nelson BH
Clin Cancer Res; 2016 May; 22(9):2226-36. PubMed ID: 26631611
[TBL] [Abstract][Full Text] [Related]
2. It's a long way to the top (if you want to personalize immunotherapy).
Haebe S; Weigert O
J Immunother Cancer; 2017; 5():6. PubMed ID: 28116089
[TBL] [Abstract][Full Text] [Related]
3. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
Wang J; Press OW; Lindgren CG; Greenberg P; Riddell S; Qian X; Laugen C; Raubitschek A; Forman SJ; Jensen MC
Mol Ther; 2004 Apr; 9(4):577-86. PubMed ID: 15093188
[TBL] [Abstract][Full Text] [Related]
4. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.
Green MR; Kihira S; Liu CL; Nair RV; Salari R; Gentles AJ; Irish J; Stehr H; Vicente-Dueñas C; Romero-Camarero I; Sanchez-Garcia I; Plevritis SK; Arber DA; Batzoglou S; Levy R; Alizadeh AA
Proc Natl Acad Sci U S A; 2015 Mar; 112(10):E1116-25. PubMed ID: 25713363
[TBL] [Abstract][Full Text] [Related]
5. Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.
Nielsen JS; Chang AR; Wick DA; Sedgwick CG; Zong Z; Mungall AJ; Martin SD; Kinloch NN; Ott-Langer S; Brumme ZL; Treon SP; Connors JM; Gascoyne RD; Webb JR; Berry BR; Morin RD; Macpherson N; Nelson BH
Oncoimmunology; 2017; 6(7):e1321184. PubMed ID: 28811957
[TBL] [Abstract][Full Text] [Related]
6. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
[TBL] [Abstract][Full Text] [Related]
7. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C; Fagman H; Hansson M; Enlund F
Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
[TBL] [Abstract][Full Text] [Related]
8. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
Neelapu SS; Baskar S; Gause BL; Kobrin CB; Watson TM; Frye AR; Pennington R; Harvey L; Jaffe ES; Robb RJ; Popescu MC; Kwak LW
Clin Cancer Res; 2004 Dec; 10(24):8309-17. PubMed ID: 15623607
[TBL] [Abstract][Full Text] [Related]
9. Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.
Miyai M; Eikawa S; Hosoi A; Iino T; Matsushita H; Isobe M; Uenaka A; Udono H; Nakajima J; Nakayama E; Kakimi K
PLoS One; 2015; 10(8):e0136086. PubMed ID: 26291626
[TBL] [Abstract][Full Text] [Related]
10. Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma.
Ying ZX; Jin M; Peterson LF; Bernard D; Saiya-Cork K; Yildiz M; Wang S; Kaminski MS; Chang AE; Klionsky DJ; Malek SN
Clin Cancer Res; 2016 Nov; 22(21):5383-5393. PubMed ID: 27267853
[TBL] [Abstract][Full Text] [Related]
11. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.
Wahlin BE; Sander B; Christensson B; Kimby E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):388-97. PubMed ID: 17255259
[TBL] [Abstract][Full Text] [Related]
12. gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes.
Braza MS; Caraux A; Rousset T; Lafaye de Micheaux S; Sicard H; Squiban P; Costes V; Klein B; Rossi JF
J Immunol; 2010 Jan; 184(1):134-40. PubMed ID: 19949101
[TBL] [Abstract][Full Text] [Related]
13. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of somatic mutations in human gastrointestinal cancers.
Tran E; Ahmadzadeh M; Lu YC; Gros A; Turcotte S; Robbins PF; Gartner JJ; Zheng Z; Li YF; Ray S; Wunderlich JR; Somerville RP; Rosenberg SA
Science; 2015 Dec; 350(6266):1387-90. PubMed ID: 26516200
[TBL] [Abstract][Full Text] [Related]
15. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
16. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.
Baskar S; Kobrin CB; Kwak LW
J Clin Invest; 2004 May; 113(10):1498-510. PubMed ID: 15146248
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
[TBL] [Abstract][Full Text] [Related]
18. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages.
Wahlin BE; Aggarwal M; Montes-Moreno S; Gonzalez LF; Roncador G; Sanchez-Verde L; Christensson B; Sander B; Kimby E
Clin Cancer Res; 2010 Jan; 16(2):637-50. PubMed ID: 20068089
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer.
Wick DA; Webb JR; Nielsen JS; Martin SD; Kroeger DR; Milne K; Castellarin M; Twumasi-Boateng K; Watson PH; Holt RA; Nelson BH
Clin Cancer Res; 2014 Mar; 20(5):1125-34. PubMed ID: 24323902
[TBL] [Abstract][Full Text] [Related]
20. Development of autologous cytotoxic CD4+ T clones in a human model of B-cell non-Hodgkin follicular lymphoma.
Mi JQ; Manches O; Wang J; Perron P; Weisbuch S; Marche PN; Renversez JC; Bensa JC; Sotto JJ; Cahn JY; Leroux D; Bonnefoix T
Br J Haematol; 2006 Nov; 135(3):324-35. PubMed ID: 16984392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
